Bitcoin Steadies Above $9,200, New High in Sights

5m
bitcoinnews

India: Facebook’s Libra Launch Might be Restrict Due to RBI’s Policy Concern

17m
coingape

QuadrigaCX CEO Set Up Fake Crypto Exchange Accounts With Customer…

27m
cryptonewmedia

Central Bank of Russia will Hold Bitcoin [BTC] Reserves Predicts…

28m
cryptonewmedia

Japan’s Line Reportedly Close to Obtaining FSA License for Japanese Crypto Exchange

28m
cryptonewmedia

Exchanges Are Exchanging In-House Tech With Service Providers?

35m
cryptodaily

Ace VPN Review: More Cons Than Pros?

40m
block

HideMyAss Review – Fast Speeds, but Privacy Concerns

41m
block

StrongVPN Review: Secure, No Logs VPN, but Some Drawbacks

42m
block

VPN Gate Review: Free VPN, but Privacy Issues

43m
block

Facebook’s Crypto Libra May Kill Launch in India, Its Biggest Market: Report

1h
cryptonewmedia

Electronics Giant Samsung Prioritizes Blockchain in 10-Year Roadmap

1h
cryptonewmedia

Can Facebook’s Libra Influence Bitcoin Price?

1h
cryptonewmedia

QuadrigaCX CEO Set Up Fake Crypto Exchange Accounts With Customer Funds

1h
coindesk

‘Dead’ CEO Cotten Embezzled Funds For Years

1h
cryptonewmedia

Bitcoin Price Rally Stalls as Open Futures Hit Record Highs

1h
coindesk

Former Circle Exec Joins Royal Bank Of Scotland To Front Fintech Project

1h
cryptodaily

Facebook’s Calibra Digital Wallet Will Not Be Available in Its Largest Markets

1h
cryptonewmedia

Italy will Use Blockchain and Fintech for Interbank Checks

1h
coinidol

PoPermissionless Blockchain Network Algorand Raises $60M in Token Auction

2h
cryptonewmedia

‘We Don’t Deal in the Speculative’

2h
cryptonewmedia

Russian Hackers May Be Responsible for Coincheck Heist

2h
cryptonewmedia

Crypto Market Showing Positive Signs: Bitcoin Cash, EOS, TRX, ADA Analysis

2h
cryptonewmedia

Tyler Winklevoss: “If Bitcoin Breaks 10k, You Can Bet It’s Going To Break 15k”

2h
cryptodaily

QuadrigaCX Update: ‘Dead’ CEO Cotten Embezzled Funds For...

2h
bitcoinist


Walmart Hedges Its Bets With 2nd Drug-Tracking Blockchain Trial

coindesk

7d ago

Walmart appears to be hedging its bets around blockchain-based pharmaceutical tracking.

The big-box retail giant said Thursday it will participate in a drug-verification pilot with IBM, KPMG and drugmaker Merck. This is the second such pilot involving Walmart to be announced in as many weeks, and it will add yet another flavor of distributed ledger technology (DLT) to the drug-tracking use case.

Just last week, CoinDesk reported that Walmart was participating in the MediLedger consortium whose members already include pharmaceutical manufacturers such as Pfizer and the three largest pharmaceutical wholesalers, McKesson, AmerisourceBergen, and Cardinal Health. But whereas MediLedger builds upon a private version of ethereum called Parity, the IBM/Walmart project will use Hyperledger Fabric.

Big retailers broadly are clearly getting more comfortable with blockchain technology and exploring multiple options. Earlier this week it emerged that Target is participating in a Hyperledger supply chain tracking project called Grid, while also pursuing its own unilateral blockchain project called ConsenSource.

Walmart was already one of the most prominent companies in the world to adopt distributed ledger technology (DLT), as a participant in IBM’s Food Trust. That system is now out of testing and is used in the wild to track the movement of fruits and vegetables from the farm to the grocery aisle. But the Bentonville behemoth is still early in its explorations of the pharmaceutical use case.

“We are learning, which is the point of these pilots, but our ultimate goal through both is to create a safer, more transparent supply chain for our customers,” said Walmart spokeswoman Marilee McInnis.

These pharmaceutical DLTs are coming to light at this moment in time because the U.S. Food and Drug Administration (FDA) is now completing its approval of platforms for inclusion in a government-mandated pilot program.

The Drug Supply Chain Security Act (DSCSA) requires firms to be able to identify, track and trace prescription medicines and vaccines distributed within the U.S., down to a fairly granular level on the packaging of these products.

The new drug pilot will build on the work Big Blue has already done with Walmart, said Mark Treshock, IBM’s blockchain solutions Leader for healthcare and life sciences.

“The project with KPMG Merck and Walmart, even though it’s a pilot, is going to be leveraging the production blockchain platforms that we have developed for Walmart with FoodTrust and also with Maersk in TradeLens,” he said, adding:

“So it’s not just a science experiment.”

While he clarified food and drugs would not co-exist on the same blockchain, Treshock said FoodTrust relies on the same sort of data standards such as GS1, as is commonly used in life sciences.

On the subject of Walmart participating in a Hyperledger pilot with IBM and at the same time working with Mediledger’s ethereum-based blockchain, Eric Garvin, co-lead at MediLedger, said it was not surprising since Walmart and IBM collaborate on FoodTrust.

“Many pharma companies are participating in multiple pilots,” he said. “The strength of the MediLedger pilot is that it includes a diverse mix of industry companies (all segments of the supply chain, large companies, small companies, brand manufacturers, generics) and has the greatest support with at least 20 companies involved.”

The FDA’s mandate for drug tracking lists “interoperability” as a key requirement and putative benefit of digitalizing the supply chain, raising the question of whether competing enterprise blockchain protocols can be made to communicate with each other – or if businesses will eventually have to consolidate platforms.

IBM’s Treshock took a philosophical view on this, telling CoinDesk:

“We feel it’s less about the technology, whether Hyperledger or ethereum – although that is certainly important – and more about interoperability at the business model level, by that I mean coming together and creating open networks.”

Regarding any copyrights issue, please contact us:content@hashbee.com.

0 comments